Press release Communiqué de presse

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter

Press release Communiqué de presse


January 15, 2002 15 January, 2002

Pheromone Sciences Corp. Completes Private Placement Offering


Pheromone Sciences Corp. (CDNX:PHS) today announced that it has completed the sale, via private placement, of 410,000 special warrants of the Company at an issue price of $0.55 per special warrant for gross proceeds of $225,500. Each special warrant will be exercisable, at no additional consideration, into one common share of the Company and one common share purchase warrant. Each warrant has a term of 18 months and will be exercisable into one common share of an exercise of $0.70 per share.

Proceeds of the offering will be used to support the Company's research and development program, ongoing operations, and business development.

Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human reproduction and sexuality.

INVESTOR CONTACT

Lorne Woods (800) 937-3095 investor@pheromonesciences.com www.pheromonesciences.com



Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The Canadian Venture Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.